Intensity-Modulated Radiotherapy
Benefit of radiotherapy for nasopharyngeal carcinoma may vary by time of day
Patients with nasopharyngeal carcinoma who received radiotherapy in the morning survived longer than those who underwent radiotherapy later in the day, according to study results.
Radiotherapy comparable to concurrent chemoradiotherapy in nasopharyngeal cancer subset
CHICAGO — Intensity-modulated radiotherapy conferred disease control and survival outcomes comparable to concurrent chemoradiotherapy but with less toxicity among patients with low-risk nasopharyngeal carcinoma, according to study results.
Radiation technique reduces symptomatic esophagitis in patients with advanced lung cancer
Esophageal-sparing intensity-modulated radiotherapy did not significantly improve esophageal quality of life but reduced incidence of symptomatic esophagitis among patients with advanced non-small cell lung cancer.
De-escalated IMRT regimen shows promise in HPV-associated oropharyngeal carcinoma
De-escalated intensity-modulated radiotherapy plus concurrent cisplatin satisfied criteria for further study among patients with HPV-related oropharyngeal squamous cell carcinoma, according to phase 2 study results.
Image-guided IMRT associated with fewer gastrointestinal adverse events in cervical cancer
Image-guided intensity-modulated radiation therapy resulted in fewer gastrointestinal adverse events than 3D conformal radiation among women with cervical cancer, according to a phase 3 study presented at the virtual ASTRO Annual Meeting.
ASTRO issues guideline on radiation therapy for cervical cancer
A new guideline issued by the American Society for Radiation Oncology addresses the use of radiation therapy for the treatment of nonmetastatic cervical cancer.
Hypofractionated, conventional radiation therapy show similar long-term efficacy in prostate cancer
Moderate hypofractionated intensity-modulated radiation therapy produced long-term outcomes similar to those of conventionally fractionated IMRT among men with localized prostate cancer, according to a 10-year update of a randomized phase 3 trial.